Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer
Since androgen receptor (AR) signaling is critically required for the development of prostate cancer (PCa), targeting AR axis has been the standard treatment of choice for advanced and metastatic PCa. Unfortunately, although the tumor initially responds to the therapy, treatment resistance eventuall...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-01-01
|
| Series: | Asian Journal of Urology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214388218300900 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850184149972811776 |
|---|---|
| author | Lingfan Xu Junyi Chen Weipeng Liu Chaozhao Liang Hailiang Hu Jiaoti Huang |
| author_facet | Lingfan Xu Junyi Chen Weipeng Liu Chaozhao Liang Hailiang Hu Jiaoti Huang |
| author_sort | Lingfan Xu |
| collection | DOAJ |
| description | Since androgen receptor (AR) signaling is critically required for the development of prostate cancer (PCa), targeting AR axis has been the standard treatment of choice for advanced and metastatic PCa. Unfortunately, although the tumor initially responds to the therapy, treatment resistance eventually develops and the disease will progress. It is therefore imperative to identify the mechanisms of therapeutic resistance and novel molecular targets that are independent of AR signaling. Recent advances in pathology, molecular biology, genetics and genomics research have revealed novel AR-independent pathways that contribute to PCa carcinogenesis and progression. They include neuroendocrine differentiation, cell metabolism, DNA damage repair pathways and immune-mediated mechanisms. The development of novel agents targeting the non-AR mechanisms holds great promise to treat PCa that does not respond to AR-targeted therapies. Keywords: Prostate cancer, Therapeutic resistance, Androgen receptor, Neuroendocrine, Cancer metabolism, DNA damage repair |
| format | Article |
| id | doaj-art-a46bbb757c1c483ca3fe4553ad88ac8b |
| institution | OA Journals |
| issn | 2214-3882 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Asian Journal of Urology |
| spelling | doaj-art-a46bbb757c1c483ca3fe4553ad88ac8b2025-08-20T02:17:06ZengElsevierAsian Journal of Urology2214-38822019-01-0161919810.1016/j.ajur.2018.11.002Targeting androgen receptor-independent pathways in therapy-resistant prostate cancerLingfan Xu0Junyi Chen1Weipeng Liu2Chaozhao Liang3Hailiang Hu4Jiaoti Huang5Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China; Department of Pathology, Duke University School of Medicine, Durham, NC, USADepartment of Urology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, ChinaDepartment of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaDepartment of Pathology, Duke University School of Medicine, Durham, NC, USADepartment of Pathology, Duke University School of Medicine, Durham, NC, USA; Corresponding author.Since androgen receptor (AR) signaling is critically required for the development of prostate cancer (PCa), targeting AR axis has been the standard treatment of choice for advanced and metastatic PCa. Unfortunately, although the tumor initially responds to the therapy, treatment resistance eventually develops and the disease will progress. It is therefore imperative to identify the mechanisms of therapeutic resistance and novel molecular targets that are independent of AR signaling. Recent advances in pathology, molecular biology, genetics and genomics research have revealed novel AR-independent pathways that contribute to PCa carcinogenesis and progression. They include neuroendocrine differentiation, cell metabolism, DNA damage repair pathways and immune-mediated mechanisms. The development of novel agents targeting the non-AR mechanisms holds great promise to treat PCa that does not respond to AR-targeted therapies. Keywords: Prostate cancer, Therapeutic resistance, Androgen receptor, Neuroendocrine, Cancer metabolism, DNA damage repairhttp://www.sciencedirect.com/science/article/pii/S2214388218300900 |
| spellingShingle | Lingfan Xu Junyi Chen Weipeng Liu Chaozhao Liang Hailiang Hu Jiaoti Huang Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer Asian Journal of Urology |
| title | Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer |
| title_full | Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer |
| title_fullStr | Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer |
| title_full_unstemmed | Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer |
| title_short | Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer |
| title_sort | targeting androgen receptor independent pathways in therapy resistant prostate cancer |
| url | http://www.sciencedirect.com/science/article/pii/S2214388218300900 |
| work_keys_str_mv | AT lingfanxu targetingandrogenreceptorindependentpathwaysintherapyresistantprostatecancer AT junyichen targetingandrogenreceptorindependentpathwaysintherapyresistantprostatecancer AT weipengliu targetingandrogenreceptorindependentpathwaysintherapyresistantprostatecancer AT chaozhaoliang targetingandrogenreceptorindependentpathwaysintherapyresistantprostatecancer AT hailianghu targetingandrogenreceptorindependentpathwaysintherapyresistantprostatecancer AT jiaotihuang targetingandrogenreceptorindependentpathwaysintherapyresistantprostatecancer |